Clinical Trial

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Study acronym: AUTUMN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-02-12 -> 2027-07-02 2026-04-23
minor Completion pushed: 2027-02-12 -> 2027-07-09 2026-04-23
Trial Details
NCT Number NCT07157787
Lead Sponsor Alexion Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Primary Membranous Nephropathy
Enrollment 30 participants
Start Date 2025-09-19
Primary Completion 2027-07-02 (estimated)
Study Completion 2027-07-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-18